{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:27:55Z","timestamp":1790771275404,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSN272201400006C"],"award-info":[{"award-number":["HHSN272201400006C"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007787","name":"National Research Centre","doi-asserted-by":"publisher","award":["MP120801"],"award-info":[{"award-number":["MP120801"]}],"id":[{"id":"10.13039\/100007787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002349","name":"Academy of Scientific Research and Technology","doi-asserted-by":"publisher","award":["7303"],"award-info":[{"award-number":["7303"]}],"id":[{"id":"10.13039\/501100002349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002349","name":"Academy of Scientific Research and Technology","doi-asserted-by":"publisher","award":["7371"],"award-info":[{"award-number":["7371"]}],"id":[{"id":"10.13039\/501100002349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic quarantined COVID-19 patients. Despite that many of the FDA-approved drugs have been showed anti-SARS-CoV-2 activity in vitro and remarkable efficacy against COVID-19 in clinical trials, no pharmaceutical products have yet been declared to be fully effective for treating COVID-19. Antidepressants comprise five major drug classes for the treatment of depression, neuralgia, migraine prophylaxis, and eating disorders which are frequently reported symptoms in COVID-19 patients. Herein, the efficacy of eight frequently prescribed FDA-approved antidepressants on the inhibition of both SARS-CoV-2 and MERS-CoV was assessed. Additionally, the in vitro anti-SARS-CoV-2 and anti-MERS-CoV activities were evaluated. Furthermore, molecular docking studies have been performed for these drugs against the spike (S) and main protease (M<jats:sup>pro<\/jats:sup>) pockets of both SARS-CoV-2 and MERS-CoV. Results showed that Amitriptyline, Imipramine, Paroxetine, and Sertraline had potential anti-viral activities. Our findings suggested that the aforementioned drugs deserve more in vitro and in vivo studies targeting COVID-19 especially for those patients suffering from depression.<\/jats:p>","DOI":"10.1038\/s41598-022-17082-6","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T12:03:18Z","timestamp":1659009798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies"],"prefix":"10.1038","volume":"12","author":[{"given":"Omnia","family":"Kutkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassmin","family":"Moatasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Al\u2010Karmalawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamada S.","family":"Abulkhair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mokhtar R.","family":"Gomaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed N.","family":"El-Taweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura M.","family":"Abo Shama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"GabAllah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina B.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazi","family":"Kayali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Kandeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"17082_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/microorganisms8070991","volume":"8","author":"A Mostafa","year":"2020","unstructured":"Mostafa, A. et al. Middle east respiratory syndrome coronavirus (MERS-CoV): state of the science. Microorganisms 8, 991 (2020).","journal-title":"Microorganisms"},{"key":"17082_CR2","doi-asserted-by":"publisher","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","volume":"253","author":"AA Elfiky","year":"2020","unstructured":"Elfiky, A. A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci 253, 117592 (2020).","journal-title":"Life Sci"},{"key":"17082_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s43141-020-00055-5","volume":"18","author":"DB Mahmoud","year":"2020","unstructured":"Mahmoud, D. B., Shitu, Z. & Mostafa, A. Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?. J. Genet. Eng. Biotechnol. 18, 35\u201335 (2020).","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"17082_CR4","doi-asserted-by":"publisher","first-page":"e05641","DOI":"10.1016\/j.heliyon.2020.e05641","volume":"6","author":"R Alnajjar","year":"2020","unstructured":"Alnajjar, R., Mostafa, A., Kandeil, A. & Al-Karmalawy, A. A. Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease. Heliyon 6, e05641 (2020).","journal-title":"Heliyon"},{"key":"17082_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3390\/pharmaceutics13030307","volume":"13","author":"MW Al-Rabia","year":"2021","unstructured":"Al-Rabia, M. W. et al. Repurposing of sitagliptin-melittin optimized nanoformula against SARS-CoV-2; antiviral screening and molecular docking studies. Pharmaceutics 13, 307 (2021).","journal-title":"Pharmaceutics"},{"key":"17082_CR6","doi-asserted-by":"publisher","first-page":"661230","DOI":"10.3389\/fchem.2021.661230","volume":"9","author":"AA Al-Karmalawy","year":"2021","unstructured":"Al-Karmalawy, A. A. et al. Molecular docking and dynamics simulation revealed the potential inhibitory activity of ACEIs against SARS-CoV-2 targeting the hACE2 receptor. Front. Chem. 9, 661230 (2021).","journal-title":"Front. Chem."},{"key":"17082_CR7","doi-asserted-by":"publisher","first-page":"100604","DOI":"10.1016\/j.imu.2021.100604","volume":"24","author":"AA Sarhan","year":"2021","unstructured":"Sarhan, A. A., Ashour, N. A. & Al-Karmalawy, A. A. The journey of antimalarial drugs against SARS-CoV-2: review article. Inform. Med. Unlocked 24, 100604 (2021).","journal-title":"Inform. Med. Unlocked"},{"key":"17082_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/ph13120443","volume":"13","author":"A Mostafa","year":"2020","unstructured":"Mostafa, A. et al. FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2. Pharmaceuticals 13, 443 (2020).","journal-title":"Pharmaceuticals"},{"key":"17082_CR9","doi-asserted-by":"publisher","first-page":"13990","DOI":"10.1039\/D0NJ02844D","volume":"44","author":"AA Al-Karmalawy","year":"2020","unstructured":"Al-Karmalawy, A. A. & Khattab, M. J. Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor. New J. Chem. 44, 13990\u201313996 (2020).","journal-title":"New J. Chem."},{"key":"17082_CR10","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.3390\/molecules24173061","volume":"24","author":"S Brogi","year":"2019","unstructured":"Brogi, S. Computational approaches for drug discovery. Molecules 24, 3061 (2019).","journal-title":"Molecules"},{"key":"17082_CR11","doi-asserted-by":"publisher","first-page":"10027","DOI":"10.1039\/D0RA10674G","volume":"11","author":"AA Elmaaty","year":"2021","unstructured":"Elmaaty, A. A. et al. Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study. RSC Adv. 11, 10027\u201310042 (2021).","journal-title":"RSC Adv."},{"key":"17082_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s43045-020-00065-6","volume":"27","author":"KE Alsharji","year":"2020","unstructured":"Alsharji, K. E. Anxiety and depression during the COVID-19 pandemic in Kuwait: the importance of physical activity. Middle East Curr. Psychiatry 27, 60 (2020).","journal-title":"Middle East Curr. Psychiatry"},{"key":"17082_CR13","doi-asserted-by":"publisher","first-page":"e0247679","DOI":"10.1371\/journal.pone.0247679","volume":"16","author":"E Alnazly","year":"2021","unstructured":"Alnazly, E., Khraisat, O. M., Al-Bashaireh, A. M. & Bryant, C. L. Anxiety, depression, stress, fear and social support during COVID-19 pandemic among Jordanian healthcare workers. PLoS ONE 16, e0247679 (2021).","journal-title":"PLoS ONE"},{"key":"17082_CR14","doi-asserted-by":"publisher","first-page":"e0246454","DOI":"10.1371\/journal.pone.0246454","volume":"16","author":"Y Li","year":"2021","unstructured":"Li, Y., Scherer, N., Felix, L. & Kuper, H. Prevalence of depression, anxiety and post-traumatic stress disorder in health care workers during the COVID-19 pandemic: a systematic review and meta-analysis. PLoS ONE 16, e0246454 (2021).","journal-title":"PLoS ONE"},{"key":"17082_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S2215-0366(20)30482-X","volume":"8","author":"D Fancourt","year":"2021","unstructured":"Fancourt, D., Steptoe, A. & Bu, F. Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: a longitudinal observational study. Lancet Psychiatry 8, 141\u2013149 (2021).","journal-title":"Lancet Psychiatry"},{"key":"17082_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/jcp.0b013e3181bb617","volume":"27","author":"F L\u00f3pez-Mu\u00f1oz","year":"2007","unstructured":"L\u00f3pez-Mu\u00f1oz, F., Alamo, C., Juckel, G. & Assion, H. J. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. J. Clin. Psychopharmacol. 27, 555\u2013559 (2007).","journal-title":"J. Clin. Psychopharmacol."},{"key":"17082_CR17","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1097\/MJT.0000000000001001","volume":"27","author":"TF da Rosa","year":"2020","unstructured":"da Rosa, T. F. et al. Repositioning or redirection of antidepressant drugs in the treatment of bacterial and fungal infections. Am. J. Ther. 27, e528\u2013e532 (2020).","journal-title":"Am. J. Ther."},{"key":"17082_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12250-019-00184-3","volume":"35","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Screening and identification of marburg virus entry inhibitors using approved drugs. Virol. Sin. 35, 235\u2013239 (2020).","journal-title":"Virol. Sin."},{"key":"17082_CR19","doi-asserted-by":"publisher","first-page":"121023","DOI":"10.1016\/j.ijpharm.2021.121023","volume":"607","author":"S Elsayed Khate","year":"2021","unstructured":"Elsayed Khate, S., El-khouly, A., Mohamed Abdel-Ba, H., Mohsen Al-mahallawi, A. & Mahmoud, G. D. Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection. Int. J. Pharm. 607, 121023 (2021).","journal-title":"Int. J. Pharm."},{"key":"17082_CR20","doi-asserted-by":"publisher","first-page":"e00489","DOI":"10.1128\/MRA.00489-20","volume":"9","author":"A Kandeil","year":"2020","unstructured":"Kandeil, A. et al. Coding-complete genome sequences of two SARS-CoV-2 isolates from Egypt. Microbiol. Resour. Announc. 9, e00489-e420 (2020).","journal-title":"Microbiol. Resour. Announc."},{"key":"17082_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3201\/eid2006.140299","volume":"20","author":"DKW Chu","year":"2014","unstructured":"Chu, D. K. W. et al. MERS coronaviruses in dromedary camels, Egypt. Emerg. Infect. Dis. 20, 1049\u20131053 (2014).","journal-title":"Emerg. Infect. Dis."},{"key":"17082_CR22","doi-asserted-by":"publisher","first-page":"7819","DOI":"10.1128\/JVI.79.12.7819-7826.2005","volume":"79","author":"CY Cheung","year":"2005","unstructured":"Cheung, C. Y. et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J. Virol. 79, 7819\u20137826 (2005).","journal-title":"J. Virol."},{"key":"17082_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF02123574","volume":"162","author":"K Tobita","year":"1975","unstructured":"Tobita, K. Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med. Microbiol. Immunol. 162, 23\u201327 (1975).","journal-title":"Med. Microbiol. Immunol."},{"key":"17082_CR24","doi-asserted-by":"crossref","unstructured":"Feoktistova, M., Geserick, P. & Leverkus, M. Crystal violet assay for determining viability of cultured cells. Cold Spring Harb. Protoc. 2016, pdb.prot087379 (2016).","DOI":"10.1101\/pdb.prot087379"},{"key":"17082_CR25","doi-asserted-by":"publisher","first-page":"e1009413","DOI":"10.1371\/journal.ppat.1009413","volume":"17","author":"MR Gomaa","year":"2021","unstructured":"Gomaa, M. R. et al. Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: results of a community-based cohort. PLoS Pathog. 17, e1009413 (2021).","journal-title":"PLoS Pathog."},{"key":"17082_CR26","unstructured":"Chemical Computing Group Inc. Molecular Operating Environment (MOE) (Chemical Computing Group Inc, 2016)."},{"key":"17082_CR27","doi-asserted-by":"publisher","first-page":"17374","DOI":"10.1039\/D0NJ04088F","volume":"44","author":"A Ghanem","year":"2020","unstructured":"Ghanem, A. et al. Tanshinone IIA synergistically enhances the antitumor activity of doxorubicin by interfering with the PI3K\/AKT\/mTOR pathway and inhibition of topoisomerase II: in vitro and molecular docking studies. New J. Chem. 44, 17374\u201317381 (2020).","journal-title":"New J. Chem."},{"key":"17082_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.sajb.2021.02.007","volume":"139","author":"RM Samra","year":"2021","unstructured":"Samra, R. M. et al. Bioassay-guided isolation of a new cytotoxic ceramide from Cyperus rotundus L. S. Afr. J. Bot. 139, 210\u2013216 (2021).","journal-title":"S. Afr. J. Bot."},{"key":"17082_CR29","doi-asserted-by":"crossref","first-page":"e22938","DOI":"10.1002\/jbt.22938","volume":"36","author":"SG Elia","year":"2021","unstructured":"Elia, S. G., Al-Karmalawy, A. A., Nasr, M. Y. & Elshal, M. F. Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: in vitro and molecular docking study. J. Biochem. Mol. Toxicol. 36, e22938 (2021).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"17082_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221\u2013224 (2020).","journal-title":"Nature"},{"key":"17082_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289\u2013293 (2020).","journal-title":"Nature"},{"key":"17082_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.celrep.2018.06.041","volume":"24","author":"S Zhang","year":"2018","unstructured":"Zhang, S. et al. Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein. Cell Rep. 24, 441\u2013452 (2018).","journal-title":"Cell Rep."},{"key":"17082_CR33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejmech.2018.03.004","volume":"150","author":"ACG Kankanamalage","year":"2018","unstructured":"Kankanamalage, A. C. G. et al. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Eur. J. Med. Chem. 150, 334\u2013346 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"17082_CR34","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1021\/acsptsci.0c00144","volume":"3","author":"SG Eliaa","year":"2020","unstructured":"Eliaa, S. G., Al-Karmalawy, A. A., Saleh, R. M. & Elshal, M. F. Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mtor pathway and inhibition of calmodulin: in vitro and molecular docking studies. ACS Pharmacol. Transl. Sci. 3, 1330\u20131338 (2020).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"17082_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2021.1918256","author":"AA Elmaaty","year":"2021","unstructured":"Elmaaty, A. A. et al. In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2021.1918256 (2021).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"17082_CR36","doi-asserted-by":"publisher","first-page":"22216","DOI":"10.1039\/D1NJ02663A","volume":"45","author":"MA Raslan","year":"2021","unstructured":"Raslan, M. A. et al. Cordyline fruticosa (L.) A. Chev. leaves: isolation, HPLC\/MS profiling and evaluation of nephroprotective and hepatoprotective activities supported by molecular docking. New J. Chem. 45, 22216\u201322233 (2021).","journal-title":"New J. Chem."},{"key":"17082_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11030-020-10070-w","volume":"25","author":"HG Ezzat","year":"2020","unstructured":"Ezzat, H. G. et al. Design, synthesis, and molecular docking studies of new [1, 2, 4] triazolo [4, 3-a] quinoxaline derivatives as potential A2B receptor antagonists. Mol. Divers. 25, 291\u2013306 (2020).","journal-title":"Mol. Divers."},{"key":"17082_CR38","doi-asserted-by":"publisher","first-page":"103781","DOI":"10.1016\/j.bioorg.2020.103781","volume":"99","author":"AM Omar","year":"2020","unstructured":"Omar, A. M. & Ihmaid, S. Habib E-SE, Althagfan SS, Ahmed S, Abulkhair HS, Ahmed HE: The rational design, synthesis, and antimicrobial investigation of 2-Amino-4-Methylthiazole analogues inhibitors of GlcN-6-P synthase. Bioorgan. Chem. 99, 103781 (2020).","journal-title":"Bioorgan. Chem."},{"key":"17082_CR39","doi-asserted-by":"publisher","first-page":"6559","DOI":"10.3390\/molecules26216559","volume":"26","author":"AA Al-Karmalawy","year":"2021","unstructured":"Al-Karmalawy, A. A. et al. Naturally available flavonoid aglycones as potential antiviral drug candidates against SARS-CoV-2. Molecules 26, 6559 (2021).","journal-title":"Molecules"},{"key":"17082_CR40","doi-asserted-by":"publisher","first-page":"16752","DOI":"10.1039\/D0NJ03611K","volume":"44","author":"AA Zaki","year":"2020","unstructured":"Zaki, A. A., Al-Karmalawy, A. A., El-Amier, Y. A. & Ashour, A. Molecular docking reveals the potential of Cleome amblyocarpa isolated compounds to inhibit COVID-19 virus main protease. New J. Chem. 44, 16752\u201316758 (2020).","journal-title":"New J. Chem."},{"key":"17082_CR41","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3390\/pathogens10050623","volume":"10","author":"R Soltane","year":"2021","unstructured":"Soltane, R. et al. Strong inhibitory activity and action modes of synthetic maslinic acid derivative on highly pathogenic coronaviruses: COVID-19 drug candidate. Pathogens 10, 623 (2021).","journal-title":"Pathogens"},{"key":"17082_CR42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3390\/horticulturae7100402","volume":"7","author":"T Shoala","year":"2021","unstructured":"Shoala, T. et al. Nanobiotechnological approaches to enhance potato resistance against potato leafroll virus (PLRV) using glycyrrhizic acid ammonium salt and salicylic acid nanoparticles. Horticulturae 7, 402 (2021).","journal-title":"Horticulturae"},{"key":"17082_CR43","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.3390\/molecules26123772","volume":"26","author":"A Abo Elmaaty","year":"2021","unstructured":"Abo Elmaaty, A. et al. Computational insights on the potential of some NSAIDs for treating COVID-19: priority set and lead optimization. Molecules 26, 3772 (2021).","journal-title":"Molecules"},{"key":"17082_CR44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11030-020-10131-0","volume":"25","author":"A Turky","year":"2021","unstructured":"Turky, A., Bayoumi, A. H., Sherbiny, F. F., El-Adl, K. & Abulkhair, H. S. Unravelling the anticancer potency of 1,2,4-triazole-N-arylamide hybrids through inhibition of STAT3: synthesis and in silico mechanistic studies. Mol. Divers. 25, 403\u2013420 (2021).","journal-title":"Mol. Divers."},{"key":"17082_CR45","doi-asserted-by":"publisher","first-page":"e2000237","DOI":"10.1002\/ardp.202000237","volume":"354","author":"MS Alesawy","year":"2020","unstructured":"Alesawy, M. S. et al. Design and discovery of new 1, 2, 4-triazolo [4, 3-c] quinazolines as potential DNA intercalators and topoisomerase II inhibitors. Arch. Pharm. 354, e2000237 (2020).","journal-title":"Arch. Pharm."},{"key":"17082_CR46","first-page":"845","volume":"83","author":"BJ McConkey","year":"2002","unstructured":"McConkey, B. J., Sobolev, V. & Edelman, M. The performance of current methods in ligand\u2013protein docking. Curr. Sci. 83, 845\u2013856 (2002).","journal-title":"Curr. Sci."},{"key":"17082_CR47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jtcme.2021.05.001","volume":"12","author":"AA Zaki","year":"2021","unstructured":"Zaki, A. A., Ashour, A., Elhady, S. S., Darwish, K. M. & Al-Karmalawy, A. A. Calendulaglycoside a showing potential activity against SARS-CoV-2 main protease: molecular docking, molecular dynamics, and SAR studies. J. Tradit. Complement. Med. 12, 16\u201334 (2021).","journal-title":"J. Tradit. Complement. Med."},{"key":"17082_CR48","doi-asserted-by":"publisher","first-page":"120185","DOI":"10.1016\/j.lfs.2021.120185","volume":"288","author":"RM Hazem","year":"2021","unstructured":"Hazem, R. M. et al. Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor. Life Sci. 288, 120185 (2021).","journal-title":"Life Sci."},{"key":"17082_CR49","doi-asserted-by":"publisher","first-page":"2000277","DOI":"10.1002\/ardp.202000277","volume":"354","author":"MH El-Shershaby","year":"2021","unstructured":"El-Shershaby, M. H. et al. Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and in silico pharmacokinetic studies of novel quinoline derivatives. Arch. Pharm. 354, 2000277 (2021).","journal-title":"Arch. Pharm."},{"key":"17082_CR50","doi-asserted-by":"publisher","first-page":"21657","DOI":"10.1039\/D1NJ02885E","volume":"45","author":"RT Diab","year":"2021","unstructured":"Diab, R. T., Abdelsamii, Z., Abd-Elaal, E. H., Al-Karmalawy, A. A. & AboDya, N. E. Design and synthesis of a new series of 3,5-disubstituted-1,2,4-oxadiazoles as potential colchicine binding site inhibitors: antiproliferative activity, molecular docking, and SAR studies. New J. Chem. 45, 21657\u201321669 (2021).","journal-title":"New J. Chem."},{"key":"17082_CR51","doi-asserted-by":"publisher","first-page":"35536","DOI":"10.1039\/D1RA04820A","volume":"11","author":"MIA Hamed","year":"2021","unstructured":"Hamed, M. I. A. et al. \u03b2-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization. RSC Adv. 11, 35536\u201335558 (2021).","journal-title":"RSC Adv."},{"key":"17082_CR52","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1815584","author":"C Shivanika","year":"2020","unstructured":"Shivanika, C., Kumar, D., Ragunathan, V., Tiwari, P. & Sumitha, A. Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1815584 (2020).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"17082_CR53","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1021\/acsomega.1c05519","volume":"7","author":"AA Elmaaty","year":"2021","unstructured":"Elmaaty, A. A. et al. In silico and in vitro studies for benzimidazole anthelmintics repurposing as VEGFR-2 antagonists: novel mebendazole-loaded mixed micelles with enhanced dissolution and anticancer activity. ACS Omega 7, 875\u2013899 (2021).","journal-title":"ACS Omega"},{"key":"17082_CR54","doi-asserted-by":"publisher","first-page":"105149","DOI":"10.1016\/j.compbiomed.2021.105149","volume":"141","author":"D Elebeedy","year":"2021","unstructured":"Elebeedy, D. et al. Abd El Maksoud AI, Al-karmalawy AA: In vitro and computational insights revealing the potential inhibitory effect of Tanshinone IIA against influenza A virus. Comput. Biol. Med. 141, 105149 (2021).","journal-title":"Comput. Biol. Med."},{"key":"17082_CR55","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/14756366.2021.2007905","volume":"37","author":"MM Khalifa","year":"2022","unstructured":"Khalifa, M. M. et al. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J. Enzyme Inhib. Med. Chem. 37, 299\u2013314 (2022).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"17082_CR56","first-page":"273","volume-title":"Profiles of Drug Substances, Excipients and Related Methodology","author":"G Indrayanto","year":"2021","unstructured":"Indrayanto, G., Putra, G. S. & Suhud, F. Chapter 6: Validation of in-vitro bioassay methods: application in herbal drug research. In Profiles of Drug Substances, Excipients and Related Methodology Vol. 46 (ed. Al-Majed, A. A.) 273\u2013307 (Academic Press, 2021)."},{"key":"17082_CR57","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1016\/S2589-7500(20)30086-8","volume":"2","author":"K Thorlund","year":"2020","unstructured":"Thorlund, K. et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digit. Health 2, e286\u2013e287 (2020).","journal-title":"Lancet Digit. Health"},{"key":"17082_CR58","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2019.20153","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 323, 1824\u20131836 (2020).","journal-title":"JAMA"},{"key":"17082_CR59","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/2045125318791944","volume":"8","author":"Y Lee","year":"2018","unstructured":"Lee, Y. et al. Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. Ther. Adv. Psychopharmacol. 8, 337\u2013348 (2018).","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"17082_CR60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3892\/br.2016.807","volume":"6","author":"RK Farooq","year":"2017","unstructured":"Farooq, R. K., Asghar, K., Kanwal, S. & Zulqernain, A. Role of inflammatory cytokines in depression: focus on interleukin-1\u03b2. Biomed. Rep. 6, 15\u201320 (2017).","journal-title":"Biomed. Rep."},{"key":"17082_CR61","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.bbi.2020.07.037","volume":"89","author":"MG Mazza","year":"2020","unstructured":"Mazza, M. G. et al. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav. Immun. 89, 594\u2013600 (2020).","journal-title":"Brain Behav. Immun."},{"key":"17082_CR62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bbi.2020.05.038","volume":"88","author":"Q Guo","year":"2020","unstructured":"Guo, Q. et al. Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: a mixed-method study. Brain Behav. Immun. 88, 17\u201327 (2020).","journal-title":"Brain Behav. Immun."},{"key":"17082_CR63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bbi.2020.05.062","volume":"88","author":"B Yuan","year":"2020","unstructured":"Yuan, B. et al. Correlation between immune response and self-reported depression during convalescence from COVID-19. Brain Behav. Immun. 88, 39\u201343 (2020).","journal-title":"Brain Behav. Immun."},{"key":"17082_CR64","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.3390\/ijerph16132255","volume":"16","author":"BX Tran","year":"2019","unstructured":"Tran, B. X. et al. Indices of change, expectations, and popularity of biological treatments for major depressive disorder between 1988 and 2017: a scientometric analysis. Int. J. Environ. Res. Public Health 16, 2255 (2019).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"17082_CR65","doi-asserted-by":"publisher","first-page":"615695","DOI":"10.3389\/fphar.2021.615695","volume":"12","author":"B Nobile","year":"2021","unstructured":"Nobile, B. et al. The anti-inflammatory effect of the tricyclic antidepressant clomipramine and its high penetration in the brain might be useful to prevent the psychiatric consequences of SARS-CoV-2 infection. Front. Pharmacol. 12, 615695 (2021).","journal-title":"Front. Pharmacol."},{"key":"17082_CR66","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.xcrm.2020.100142","volume":"1","author":"A Carpinteiro","year":"2020","unstructured":"Carpinteiro, A. et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep. Med. 1, 100142 (2020).","journal-title":"Cell Rep. Med."},{"key":"17082_CR67","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S2214-109X(21)00448-4","volume":"10","author":"G Reis","year":"2022","unstructured":"Reis, G. et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob. Health 10, e42\u2013e51 (2022).","journal-title":"Lancet Glob. Health"},{"key":"17082_CR68","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1111\/bph.12720","volume":"171","author":"B Guardiola-Lemaitre","year":"2014","unstructured":"Guardiola-Lemaitre, B. et al. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br. J. Pharmacol. 171, 3604\u20133619 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"17082_CR69","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/17460441.2019.1546691","volume":"14","author":"X Gonda","year":"2019","unstructured":"Gonda, X., Sharma, S. R. & Tarazi, F. I. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin. Drug Discov. 14, 81\u201389 (2019).","journal-title":"Expert Opin. Drug Discov."},{"key":"17082_CR70","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s00213-022-06105-9","volume":"239","author":"D Nogo","year":"2022","unstructured":"Nogo, D. et al. The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits. Psychopharmacology 239, 2011\u20132039 (2022).","journal-title":"Psychopharmacology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17082-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17082-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17082-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T02:24:09Z","timestamp":1700879049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17082-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["17082"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-17082-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12920"}}